- Diabetes and obesity drug developer Novo Nordisk A/S NVO raised its 2023 operating profit and sales growth expectations supported by stronger expected sales of its Wegovy (semaglutide) obesity drug.
- "The sales outlook for 2023 is raised, primarily reflecting Wegovy prescription trends in the first quarter and higher full-year expectations for sales of Wegovy in the U.S.," Novo Nordisk said.
- Also Read: Novo Nordisk's Obesity Drug May Find Place On World Health Organization's 'Essential Medicines List'
- Novo now expects sales growth in local currencies for 2023 between 24%-30% and operating profit growth between 28%-34%, up from a February guidance of 13%-19% for both metrics.
- The updated sales outlook also reflects higher full-year expectations for Ozempic sales, based on the same ingredient as Wegovy, mainly in the U.S., following accelerated volume growth of the GLP-1 class.
- Novo also said that a second contract manufacturer is ready to begin production of Wegovy, which would increase supply.
- In Q1 of 2023, sales increased by 25%, and operating profit rose by 28% in local currencies.
- Wednesday, the Canadian biotech Aspect Biosystems announced a partnership with Novo Nordisk to produce bioprinted tissue therapeutics for diabetes.
- In this deal, Aspect will receive $75 million from Novo Nordisk in initial payments, up to $650 million in future milestone payments per product arising from the collaboration, and tiered royalties.
- Price Action: NVO shares are up 1.98% at $166.78 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
